Last reviewed · How we verify

Guideline-directed therapy

St. Antonius Hospital · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Guideline-directed therapy is a Small molecule drug developed by St. Antonius Hospital. It is currently FDA-approved.

Guideline-directed therapy is used to treat various conditions, including Acute Heart Failure, Coronavirus Infection COVID-19, HER-2 Gene Amplification, Cancer, and Coronary Artery Disease. The therapy involves interventions such as goal-directed preload and afterload decrement, exposure to a "TOR" device, and exposure to a switched off "TOR" device, as studied in clinical trials like the Goal-Directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study (GALACTIC).

At a glance

Generic nameGuideline-directed therapy
SponsorSt. Antonius Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Guideline-directed therapy

What is Guideline-directed therapy?

Guideline-directed therapy is a Small molecule drug developed by St. Antonius Hospital.

Who makes Guideline-directed therapy?

Guideline-directed therapy is developed and marketed by St. Antonius Hospital (see full St. Antonius Hospital pipeline at /company/st-antonius-hospital).

What development phase is Guideline-directed therapy in?

Guideline-directed therapy is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing